가스 교환 폐기능 검사 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Gas Exchange Pulmonary Function Testing Market was valued at USD 249.3 million in 2024 and is estimated to grow at a CAGR of 6.3% to reach USD 450.7 million by 2034.

Growth in this market is being propelled by rising cases of chronic respiratory conditions, increasing adoption of diagnostic tools such as DLCO and CPET, and the expansion of hospital-based diagnostic facilities. This market supports healthcare providers, technology firms, payers, and life sciences companies with advanced diagnostic technologies designed to improve clinical workflows, ensure regulatory compliance, and enhance patient care. Product offerings include gas diffusion analyzers, CPET systems, spirometry devices, and digital platforms integrated with AI and telehealth capabilities. These innovations are reshaping diagnostic pathways by enabling quicker, more accurate, and remote testing capabilities. With rapid growth in healthcare infrastructure, particularly in developing regions, combined with a broader range of portable and user-friendly testing tools, access to pulmonary testing has never been more widespread. Continuous investment in R&D, along with strategic alliances and geographic expansion, is driving competition and product innovation. In developed markets, favorable reimbursement frameworks and a growing shift toward preventive respiratory care are accelerating the adoption of advanced pulmonary function testing systems.

In 2024, the portable device segment held an 82.8% share owing to the increased preference for home-based and point-of-care respiratory monitoring. Patients and healthcare professionals are embracing portable pulmonary function tools to manage conditions such as asthma, COPD, and interstitial lung diseases outside clinical settings. These devices, supported by advancements in digital connectivity, compact designs, and intuitive interfaces, are proving to be ideal for home monitoring, enabling frequent testing and remote disease management without compromising accuracy or performance.

The gas diffusion tests segment held a 61% share in 2024 and is anticipated to reach USD 263.7 million by 2034. These tests, especially DLCO, remain vital in assessing how efficiently the lungs transfer gases like oxygen and carbon dioxide. With rising global cases of interstitial lung diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease, the demand for accurate diffusion testing continues to climb. Hospitals, diagnostic labs, and specialty clinics are increasingly relying on this segment for early detection and management of complex pulmonary disorders.

North America Gas Exchange Pulmonary Function Testing Market held 40.2% share in 2024, driven by advanced diagnostic infrastructure, high prevalence of chronic respiratory conditions, and accelerated uptake of cutting-edge technologies. The growing elderly population and their increased vulnerability to conditions like pulmonary fibrosis and COPD further support the demand for precise gas exchange assessments and CPET systems in the region.

Leading players in the Global Gas Exchange Pulmonary Function Testing Market include Geratherm Respiratory, MGC Diagnostics Holdings, Sibelmed, Schiller, COSMED, ndd Medical Technologies, Vitalograph, Vyaire, Morgan Scientific, ECO MEDICS, CORTEX, and CHEST M.I. To boost their foothold in the Global Gas Exchange Pulmonary Function Testing Market, key companies are heavily investing in product innovation focused on digital integration, AI-based analytics, and remote monitoring capabilities. Strategic partnerships with hospitals, diagnostic labs, and telehealth providers help expand distribution and clinical adoption. Many players are also increasing their focus on emerging markets through regional manufacturing, improved logistics, and training programs for medical professionals.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 System type trends
  • 2.2.3 Test method trends
  • 2.2.4 Application trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of respiratory diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Growing demand for home care solutions
    • 3.2.1.4 Supportive government initiatives and reimbursement policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with equipment
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration with digital health platforms
    • 3.2.3.2 Development of portable and handheld device
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
  • 3.6.1 Current technological trends
    • 3.6.1.1 Advanced spirometry platforms with digital interfaces
    • 3.6.1.2 Cardiopulmonary exercise testing (CPET) systems
    • 3.6.1.3 Gas diffusion analyzers (DLCO)
  • 3.6.2 Emerging technologies
    • 3.6.2.1 AI-driven predictive analytics for respiratory diagnostics
    • 3.6.2.2 Remote monitoring and tele-PFT solutions
    • 3.6.2.3 Wearable pulmonary function monitoring devices
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Value chain analysis
• 3.11 Future market trends
  • 3.11.1 Growth of home-based pulmonary function testing
  • 3.11.2 Expansion of portable and patient-centric devices
  • 3.11.3 Integration of PFT systems with digital health platforms

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 LAMEA
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New service type launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By System Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Portable
• 5.3 Stationary

Chapter 6 Market Estimates and Forecast, By Test Method, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Gas diffusion tests
• 6.3 Cardiopulmonary exercise testing (CPET)

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Chronic obstructive pulmonary disease
• 7.3 Asthma
• 7.4 Chronic shortness of breath
• 7.5 Pulmonary fibrosis
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & clinics
• 8.3 Diagnostic centers
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 CHEST M.I.
• 10.2 CORTEX
• 10.3 COSMED
• 10.4 ECO MEDICS
• 10.5 Geratherm Respiratory
• 10.6 Morgan Scientific
• 10.7 MGC Diagnostics Holdings
• 10.8 ndd Medical Technologies
• 10.9 Schiller
• 10.10 Sibelmed
• 10.11 Vitalograph
• 10.12 Vyaire